Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,045
  • Shares Outstanding, K 71,040
  • Annual Sales, $ 500 K
  • Annual Income, $ -27,360 K
  • 36-Month Beta 0.82
  • Price/Sales 86.77
  • Price/Cash Flow N/A
  • Price/Book 1.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.81
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/13/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.10
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +58.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.53 +11.68%
on 11/21/18
0.66 -10.32%
on 11/30/18
-0.05 (-7.52%)
since 11/14/18
3-Month
0.53 +11.68%
on 11/21/18
0.88 -32.74%
on 10/03/18
-0.17 (-22.12%)
since 09/14/18
52-Week
0.53 +11.68%
on 11/21/18
2.38 -75.13%
on 02/13/18
-1.13 (-65.59%)
since 12/14/17

Most Recent Stories

More News
Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MyoKardia, Inc. (NASDAQ:MYOK),...

BRS : 2.93 (-13.31%)
CATB : 0.59 (-4.53%)
CASA : 13.85 (-6.48%)
CHEF : 36.46 (-2.77%)
EPE : 0.81 (-14.36%)
MYOK : 53.26 (-3.50%)
Catabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that data from the Phase 1 MoveDMD clinical trial of edasalonexent were published...

CATB : 0.59 (-4.53%)
Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2018, and reviewed...

CATB : 0.59 (-4.53%)
Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystrophies

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced a collaboration with Pradeep Mammen, MD, FACC, FAHA, founder and Medical...

CATB : 0.59 (-4.53%)
Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar: "PolarisDMD: Phase 3 Clinical...

CATB : 0.59 (-4.53%)
Catabasis Pharmaceuticals to Report Third Quarter 2018 Financial Results and Recent Corporate Developments on Tuesday, November 13

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2018 financial results before the Nasdaq Global Market open on...

CATB : 0.59 (-4.53%)
Bet on Rising P/E Investing With These 5 Top-Ranked Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

CATB : 0.59 (-4.53%)
PCH : 33.87 (-3.12%)
EBAY : 28.91 (-0.38%)
NLST : 0.4250 (-7.10%)
TLRD : 14.48 (+2.48%)
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the initiation of PolarisDMD, the Company's Phase 3 trial for edasalonexent...

CATB : 0.59 (-4.53%)
Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress

-- Presentations on MoveDMD Clinical Results and Polaris DMD Phase 3 Design -

CATB : 0.59 (-4.53%)
Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study

Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.

SPPI : 11.58 (unch)
CATB : 0.59 (-4.53%)
AZN : 39.15 (-0.23%)
PCRX : 45.26 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 0.67
1st Resistance Point 0.65
Last Price 0.59
1st Support Level 0.60
2nd Support Level 0.57

See More

52-Week High 2.38
Fibonacci 61.8% 1.67
Fibonacci 50% 1.46
Fibonacci 38.2% 1.24
Last Price 0.59
52-Week Low 0.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar